Our Diverse, Dedicated and Qualified Team

Jean-Marc Limacher is a medical oncologist who graduated from the Faculty of Medicine of Strasbourg.
He began his career at the University Hospitals of Strasbourg, where he set up the cancer family clinic.
In 2004, he joined Transgene where he served as Medical Director and was responsible for the clinical development of several cancer immunotherapy products. More than 60 publications reflect his work.
In 2016 he filed a patent application for an innovative immunotherapy and co-founded ODIMMA THERAPEUTICS in 2017, with Jessica Matta.
He is today Chairman and Chief Medical Officer of the company.

Nicolas Ferry was trained as an M.D., Ph.D. from Paris University. He served as a scientist at the French National Institute for Health Sciences (INSERM) for more than 25 years, and co-authored more than 120 publications.
Nicolas is a former director for biologics at the French regulatory authority (ANSM) from 2011 to 2016 and member of the CAT at EMA during the same period
Nicolas worked at Servier and Coave Therapeutics and was referent for bioproduction and biotherapy at INSERM ITMO Health Technology.

Pascale Balducchi is a doctor in veterinary medicine who specialised in toxicology. She began her career in the healthcare industry by joining the teams of Sanofi and Pierre Fabre Oncology, first in the research department, then in international marketing.
She participated in the clinical development and launch of several products in Europe and USA and obtained in 1994 an MBA from HEC Paris and New York University.
She worked with biotech companies, advising them on development strategy, fundraising and project management and within this activity, she participated in several onco-immunology projects some of which with Dr. Jean-Marc Limacher.
In 2021, she joined the ODIMMA THERAPEUTICS team as Business Manager with the mission of improving the strategy and business partnering of the Company.

Rémi Gloeckler is a recognised expert in pharmaceutical manufacturing and quality control of biotherapies for clinical use.
He founded PharminCell, in which he serves as CEO to provide consulting services to biotechnology companies in their pharmaceutical development.
Thanks to its 30 years professional experience, Rémi Gloeckler is a key person to understand all stages of development and to manufacture our product under regulatory conditions.
He accompanies ODIMMA THERAPEUTICS on pharmaceutical development issues and his input is all the more important as our product is innovative.

Jérémy Amzallag is an industrial pharmacist specilised in quality assurance in pharmaceutical production and quality control of biotherapies.
He founded EYLIO, in which he serves as Qualified Person to provide Batch release to biotechnology companies in their clinical trials.
Since the beginning of his professional career, Jérémy Amzallag has held several positions in operational quality on production sites and in the release of clinical and commercial lots.
Jérémy Amzallag supports ODIMMA THERAPEUTICS in the release of future clinical batches as well as in regulatory strategies.

Ronald Rooke on got his PhD from McGill University in Microbiology and Immunology, specializing in Virology.
He gained fundamental knowledge in Immunology during his post-doctoral fellow which he applied to oncology throughout his career.
As Director of the Immunopharmacology Department at Transgene, Ron supervised the elaboration of methods and models required to understand the mode of action of MVA-based Therapeutic cancer vaccine.
His expertise also encompass, Clinical support, Biomarker identification and Quality Control. More recently, Ron gained experience in Immunostimulatory small molecule development.

Célia Matta holds a PhD in Life and Health Sciences at the University of Strasbourg.
She joined ODIMMA THERAPEUTICS team as a preclinical research officer.
She is also in charge of the organisation of the research laboratory, the planning of manipulations as well as the purchase of equipment and consumables.
In addition to these functions, Célia Matta is in charge of the implementation and respect of safety, health and environment (HSE) procedures.

Cécile Hugel obtained in 2018 a degree in Biotechnological Engineering from the Ecole Supérieure des Biotechnologies de Strasbourg and a Master's degree in Drug Design and Production from the University of Pharmacy in Strasbourg.
She joined the ODIMMA THERAPEUTICS team as a project engineer.
She participates at the elaboration and management of all the scientific projects of the company.